Michael S. Rabson

Blackfynn, Inc. provides treatments for neurological disease. Its new tools and technologies are generating. The company was founded by Amanda Christini and Joost Wagenaar and is headquartered in Philadelphia, PA.

Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Avidia, Inc. developed pharmaceutical products. The company developed a novel, proprietary class of small therapeutic proteins. The company was headquartered in Mountain View, CA.

Wilson Sonsini Goodrich & Rosati PC provides legal services. Its services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law. The company was founded in 1961 and is headquartered in Palo Alto, CA.